Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGENDER SVF for Diabetic Foot Ulcers
2024-516342-19-00Phase 2Authorised
- Sponsor
- Assistance Publique–Hôpitaux de Marseille
- Start
- Sep 2024
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous adipose-derived stromal vascular fraction cells in diabetic foot ulcer (DFU), diabetes mellitus type 1 (T1D) and type 2 diabetes mellitus (T2DM), sponsored by Assistance Publique–Hôpitaux de Marseille. Primary endpoint: Complete wound healing by week 20. Planned start Sep 2024; status: authorised.
02
Drugs
autologous adipose-derived stromal vascular fraction cells
03
Conditions
diabetic foot ulcer (DFU)diabetes mellitus type 1 (T1D)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2024-516342-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516342-19-00.